Travere Accounts Payable vs Total Liab Analysis

TVTX Stock

USD 7.42 0.40 5.70%

Travere Therapeutics financial indicator trend analysis is much more than just breaking down Travere Therapeutics prevalent accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Travere Therapeutics is a good investment. Please check the relationship between Travere Therapeutics Accounts Payable and its Total Liab accounts. Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Travere Therapeutics. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in estimate.

For more information on how to buy Travere Stock please use our How to Invest in Travere Therapeutics guide.

Accounts Payable vs Total Liab

Accounts Payable vs Total Liab Correlation Analysis

The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Travere Therapeutics Accounts Payable account and Total Liab. At this time, the significance of the direction appears to have very strong relationship.

The correlation between Travere Therapeutics' Accounts Payable and Total Liab is 0.81. Overlapping area represents the amount of variation of Accounts Payable that can explain the historical movement of Total Liab in the same time period over historical financial statements of Travere Therapeutics, assuming nothing else is changed. The correlation between historical values of Travere Therapeutics' Accounts Payable and Total Liab is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Accounts Payable of Travere Therapeutics are associated (or correlated) with its Total Liab. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Total Liab has no effect on the direction of Accounts Payable i.e., Travere Therapeutics' Accounts Payable and Total Liab go up and down completely randomly.

Correlation Coefficient

0.81

Relationship Direction	Positive
Relationship Strength	Strong

View All Relationships

Accounts Payable

An accounting item on the balance sheet that represents Travere Therapeutics obligation to pay off a short-term debt to its creditors. The accounts payable entry is usually reported under current liabilities. If accounts payable of Travere Therapeutics are not paid within the agreed terms, the payables are considered to be in default, which may trigger a penalty or interest payment, or the revocation of additional credit from the supplier. Accounts payable may also be considered a source of cash, since they represent funds being borrowed from suppliers. Given these cash flow considerations, suppliers have a natural inclination to push for shorter payment terms, while creditors want to lengthen the payment terms. The amount a company owes to suppliers or vendors for products or services received but not yet paid for. It represents the company's short-term liabilities.

Total Liab

The total amount of all liabilities that a company has, including both short-term and long-term liabilities.

Most indicators from Travere Therapeutics' fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Travere Therapeutics current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Travere Therapeutics. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in estimate.

For more information on how to buy Travere Stock please use our How to Invest in Travere Therapeutics guide.At this time, Travere Therapeutics' Selling General Administrative is fairly stable compared to the past year. Tax Provision is likely to rise to about 234.2 K in 2024, whereas Issuance Of Capital Stock is likely to drop slightly above 113.4 M in 2024.

	2021	2022	2023	2024 (projected)
Research Development	210.3M	235.8M	237.7M	122.4M
Depreciation And Amortization	2.2M	7.3M	44.9M	47.2M

Research Development Depreciation And Amortization

Travere Therapeutics fundamental ratios Correlations

	Total Assets	Short Long Term Debt Total	Other Current Liab	Total Current Liabilities	Total Stockholder Equity	Net Debt	Retained Earnings	Accounts Payable	Cash	Cash And Short Term Investments	Common Stock Total Equity	Common Stock Shares Outstanding	Non Current Liabilities Total	Other Stockholder Equity	Total Liab	Total Current Assets	Short Term Debt	Common Stock	Property Plant And Equipment Net	Current Deferred Revenue	Non Current Assets Total	Non Currrent Assets Other	Other Current Assets	Intangible Assets	Short Term Investments	Property Plant And Equipment Gross
Total Assets		0.72	0.77	0.87	0.8	0.54	-0.68	0.6	0.83	0.98	0.92	0.47	0.85	0.82	0.85	0.99	0.11	0.94	0.62	0.2	0.93	0.31	0.67	0.86	0.96	0.6
Short Long Term Debt Total	0.72		0.81	0.78	0.27	0.96	-0.97	0.81	0.52	0.78	0.79	0.48	0.97	0.95	0.97	0.76	-0.16	0.77	0.87	-0.27	0.58	0.65	0.82	0.46	0.84	0.89
Other Current Liab	0.77	0.81		0.8	0.5	0.74	-0.85	0.84	0.52	0.74	0.8	0.43	0.85	0.91	0.88	0.77	0.0	0.87	0.77	0.02	0.74	0.71	0.94	0.64	0.79	0.8
Total Current Liabilities	0.87	0.78	0.8		0.5	0.67	-0.76	0.67	0.63	0.85	0.93	0.43	0.82	0.8	0.86	0.86	0.29	0.95	0.66	0.17	0.8	0.4	0.7	0.71	0.86	0.66
Total Stockholder Equity	0.8	0.27	0.5	0.5		0.06	-0.22	0.34	0.75	0.72	0.57	0.25	0.45	0.48	0.46	0.75	0.25	0.63	0.21	0.49	0.85	0.03	0.43	0.85	0.67	0.2
Net Debt	0.54	0.96	0.74	0.67	0.06		-0.94	0.79	0.26	0.6	0.65	0.43	0.88	0.86	0.88	0.59	-0.21	0.63	0.78	-0.37	0.4	0.71	0.81	0.28	0.71	0.83
Retained Earnings	-0.68	-0.97	-0.85	-0.76	-0.22	-0.94		-0.83	-0.5	-0.74	-0.8	-0.49	-0.93	-0.96	-0.94	-0.73	0.24	-0.78	-0.92	0.33	-0.51	-0.74	-0.84	-0.38	-0.8	-0.95
Accounts Payable	0.6	0.81	0.84	0.67	0.34	0.79	-0.83		0.38	0.63	0.65	0.38	0.77	0.86	0.81	0.62	-0.08	0.66	0.66	-0.19	0.51	0.74	0.88	0.43	0.71	0.74
Cash	0.83	0.52	0.52	0.63	0.75	0.26	-0.5	0.38		0.84	0.76	0.34	0.66	0.65	0.65	0.82	0.08	0.74	0.59	0.2	0.76	0.08	0.34	0.73	0.74	0.53
Cash And Short Term Investments	0.98	0.78	0.74	0.85	0.72	0.6	-0.74	0.63	0.84		0.93	0.5	0.88	0.85	0.87	1.0	-0.03	0.92	0.7	0.06	0.84	0.33	0.65	0.75	0.98	0.68
Common Stock Total Equity	0.92	0.79	0.8	0.93	0.57	0.65	-0.8	0.65	0.76	0.93		0.46	0.87	0.85	0.88	0.93	0.07	0.96	0.74	0.03	0.8	0.45	0.67	0.72	0.92	0.72
Common Stock Shares Outstanding	0.47	0.48	0.43	0.43	0.25	0.43	-0.49	0.38	0.34	0.5	0.46		0.5	0.5	0.48	0.5	-0.15	0.44	0.49	-0.15	0.34	0.32	0.43	0.26	0.52	0.49
Non Current Liabilities Total	0.85	0.97	0.85	0.82	0.45	0.88	-0.93	0.77	0.66	0.88	0.87	0.5		0.96	0.99	0.87	-0.12	0.86	0.84	-0.15	0.73	0.57	0.81	0.63	0.92	0.84
Other Stockholder Equity	0.82	0.95	0.91	0.8	0.48	0.86	-0.96	0.86	0.65	0.85	0.85	0.5	0.96		0.97	0.84	-0.13	0.85	0.88	-0.15	0.7	0.69	0.89	0.58	0.89	0.91
Total Liab	0.85	0.97	0.88	0.86	0.46	0.88	-0.94	0.81	0.65	0.87	0.88	0.48	0.99	0.97		0.87	-0.03	0.88	0.84	-0.09	0.76	0.58	0.84	0.66	0.91	0.85
Total Current Assets	0.99	0.76	0.77	0.86	0.75	0.59	-0.73	0.62	0.82	1.0	0.93	0.5	0.87	0.84	0.87		0.01	0.93	0.68	0.1	0.87	0.35	0.68	0.78	0.98	0.66
Short Term Debt	0.11	-0.16	0.0	0.29	0.25	-0.21	0.24	-0.08	0.08	-0.03	0.07	-0.15	-0.12	-0.13	-0.03	0.01		0.11	-0.27	0.76	0.37	-0.37	-0.04	0.46	-0.06	-0.26
Common Stock	0.94	0.77	0.87	0.95	0.63	0.63	-0.78	0.66	0.74	0.92	0.96	0.44	0.86	0.85	0.88	0.93	0.11		0.72	0.14	0.86	0.45	0.74	0.76	0.92	0.7
Property Plant And Equipment Net	0.62	0.87	0.77	0.66	0.21	0.78	-0.92	0.66	0.59	0.7	0.74	0.49	0.84	0.88	0.84	0.68	-0.27	0.72		-0.27	0.44	0.6	0.7	0.31	0.72	0.99
Current Deferred Revenue	0.2	-0.27	0.02	0.17	0.49	-0.37	0.33	-0.19	0.2	0.06	0.03	-0.15	-0.15	-0.15	-0.09	0.1	0.76	0.14	-0.27		0.41	-0.54	-0.02	0.5	0.01	-0.28
Non Current Assets Total	0.93	0.58	0.74	0.8	0.85	0.4	-0.51	0.51	0.76	0.84	0.8	0.34	0.73	0.7	0.76	0.87	0.37	0.86	0.44	0.41		0.21	0.63	0.98	0.82	0.42
Non Currrent Assets Other	0.31	0.65	0.71	0.4	0.03	0.71	-0.74	0.74	0.08	0.33	0.45	0.32	0.57	0.69	0.58	0.35	-0.37	0.45	0.6	-0.54	0.21		0.74	0.08	0.43	0.67
Other Current Assets	0.67	0.82	0.94	0.7	0.43	0.81	-0.84	0.88	0.34	0.65	0.67	0.43	0.81	0.89	0.84	0.68	-0.04	0.74	0.7	-0.02	0.63	0.74		0.52	0.75	0.77
Intangible Assets	0.86	0.46	0.64	0.71	0.85	0.28	-0.38	0.43	0.73	0.75	0.72	0.26	0.63	0.58	0.66	0.78	0.46	0.76	0.31	0.5	0.98	0.08	0.52		0.72	0.29
Short Term Investments	0.96	0.84	0.79	0.86	0.67	0.71	-0.8	0.71	0.74	0.98	0.92	0.52	0.92	0.89	0.91	0.98	-0.06	0.92	0.72	0.01	0.82	0.43	0.75	0.72		0.72
Property Plant And Equipment Gross	0.6	0.89	0.8	0.66	0.2	0.83	-0.95	0.74	0.53	0.68	0.72	0.49	0.84	0.91	0.85	0.66	-0.26	0.7	0.99	-0.28	0.42	0.67	0.77	0.29	0.72

Click cells to compare fundamentals

Travere Therapeutics Account Relationship Matchups

Travere Therapeutics fundamental ratios Accounts

	2019	2020	2021	2022	2023	2024 (projected)
Total Assets	604.8M	607.4M	776.6M	672.6M	788.9M	461.7M
Short Long Term Debt Total	204.9M	215.3M	262.0M	407.5M	404.8M	425.0M
Other Current Liab	68.8M	80.5M	88.8M	108.5M	124.2M	130.4M
Total Current Liabilities	95.4M	92.7M	124.1M	142.2M	177.9M	89.6M
Total Stockholder Equity	221.2M	211.2M	302.1M	42.9M	200.8M	168.0M
Net Debt	142.4M	130.6M	96.2M	345.8M	346.6M	363.9M
Retained Earnings	(416.4M)	(585.9M)	(766.0M)	(1.0B)	(1.1B)	(1.1B)
Accounts Payable	26.6M	12.1M	15.1M	17.3M	41.7M	43.8M
Cash	62.4M	84.8M	165.8M	61.7M	58.2M	58.0M
Cash And Short Term Investments	398.5M	361.6M	552.9M	450.2M	566.9M	284.6M
Common Stock Shares Outstanding	42.3M	47.5M	59.8M	63.8M	74.3M	45.7M
Liabilities And Stockholders Equity	604.8M	607.4M	776.6M	672.6M	788.9M	461.7M
Non Current Liabilities Total	288.2M	303.6M	350.4M	487.6M	410.2M	430.7M
Other Stockholder Equity	636.9M	798.0M	1.1B	1.1B	1.3B	1.4B
Total Liab	383.6M	396.2M	474.5M	629.7M	588.1M	617.5M
Total Current Assets	429.1M	410.4M	582.8M	486.4M	616.8M	316.3M
Short Term Debt	2.6M	357K	3.9M	4.4M	4.9M	8.1M
Property Plant And Equipment Net	2.9M	9.4M	34.3M	30.0M	25.5M	26.8M
Current Deferred Revenue	(2.6M)	(357K)	16.3M	12.0M	7.1M	11.3M
Non Current Assets Total	175.7M	197.0M	193.8M	186.1M	172.1M	169.6M
Non Currrent Assets Other	14.7M	33.5M	11.1M	11.1M	42.1M	44.2M
Other Current Assets	6.4M	8.1M	6.5M	12.6M	19.3M	20.3M
Intangible Assets	157.2M	153.2M	148.4M	145.0M	103.7M	140.4M
Short Term Investments	336.1M	276.8M	387.1M	388.6M	508.7M	288.4M
Property Plant And Equipment Gross	2.9M	9.4M	34.3M	30.0M	33.0M	34.6M
Accumulated Other Comprehensive Income	726K	(902K)	(562K)	(2.9M)	(1.5M)	(1.4M)
Net Receivables	18.0M	33.1M	16.2M	16.6M	21.2M	21.3M
Inventory	6.1M	7.6M	7.3M	6.9M	9.4M	6.0M
Other Liab	83.3M	59.9M	92.4M	84.5M	76.1M	67.7M
Net Tangible Assets	63.1M	57.1M	153.7M	(102.2M)	(92.0M)	(87.4M)
Other Assets	14.7M	7.8M	11.1M	36K	32.4K	30.8K
Long Term Debt	204.9M	215.3M	226.6M	375.5M	377.3M	257.7M
Net Invested Capital	426.1M	426.6M	528.7M	418.4M	578.1M	511.0M
Non Current Liabilities Other	83.3M	88.2M	20.4M	73.6M	8.5M	8.1M
Net Working Capital	333.6M	317.7M	458.7M	344.3M	438.9M	396.7M
Property Plant Equipment	2.9M	35.1M	11.1M	9.0M	10.4M	11.8M

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

V	Visa Class A
BAC	Bank of America
GM	General Motors

When determining whether Travere Therapeutics offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Travere Therapeutics' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Travere Therapeutics Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Travere Therapeutics Stock:

How To Invest In Travere

Details

Is Travere Stock a good investment?

Details

What is Travere Therapeutics' Net Worth?

Details

Largest Biotechnology Companies

View

Largest Pharmaceuticals, Biotechnology & Life Sciences Companies

View

Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Travere Therapeutics. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in estimate.

For more information on how to buy Travere Stock please use our How to Invest in Travere Therapeutics guide.

You can also try the Watchlist Optimization module to optimize watchlists to build efficient portfolios or rebalance existing positions based on the mean-variance optimization algorithm.

Complementary Tools for Travere Stock analysis

When running Travere Therapeutics' price analysis, check to measure Travere Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Travere Therapeutics is operating at the current time. Most of Travere Therapeutics' value examination focuses on studying past and present price action to predict the probability of Travere Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Travere Therapeutics' price. Additionally, you may evaluate how the addition of Travere Therapeutics to your portfolios can decrease your overall portfolio volatility.

	Content Syndication Quickly integrate customizable finance content to your own investment portal
	Global Correlations Find global opportunities by holding instruments from different markets
	Sync Your Broker Sync your existing holdings, watchlists, positions or portfolios from thousands of online brokerage services, banks, investment account aggregators and robo-advisors.
	FinTech Suite Use AI to screen and filter profitable investment opportunities
	Portfolio Volatility Check portfolio volatility and analyze historical return density to properly model market risk
	Sectors List of equity sectors categorizing publicly traded companies based on their primary business activities
	Price Ceiling Movement Calculate and plot Price Ceiling Movement for different equity instruments
	Portfolio Analyzer Portfolio analysis module that provides access to portfolio diagnostics and optimization engine
	Risk-Return Analysis View associations between returns expected from investment and the risk you assume
	USA ETFs Find actively traded Exchange Traded Funds (ETF) in USA
	Options Analysis Analyze and evaluate options and option chains as a potential hedge for your portfolios
	Volatility Analysis Get historical volatility and risk analysis based on latest market data

Is Travere Therapeutics' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Travere Therapeutics. If investors know Travere will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Travere Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.

Earnings Share

(5.41)

Revenue Per Share

2.035

Quarterly Revenue Growth

0.339

Return On Assets

(0.36)

Return On Equity

(3.16)

The market value of Travere Therapeutics is measured differently than its book value, which is the value of Travere that is recorded on the company's balance sheet. Investors also form their own opinion of Travere Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Travere Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Travere Therapeutics' market value can be influenced by many factors that don't directly affect Travere Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.

Please note, there is a significant difference between Travere Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Travere Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Travere Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

Travere Accounts Payable vs Total Liab Analysis

Accounts Payable vs Total Liab

Accounts Payable vs Total Liab Correlation Analysis

Correlation Coefficient

Accounts Payable

Total Liab

Travere Therapeutics fundamental ratios Correlations

Travere Therapeutics Account Relationship Matchups

High Positive Relationship

High Negative Relationship

Travere Therapeutics fundamental ratios Accounts

Also Currently Popular

Complementary Tools for Travere Stock analysis

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY

Total Current Assets	+ 1.0	Cash And Short Term Investments
Total Current Assets	+ 0.99	Total Assets
Total Liab	+ 0.99	Non Current Liabilities Total
Property Plant And Equipment Gross	+ 0.99	Property Plant And Equipment Net
Cash And Short Term Investments	+ 0.98	Total Assets
Short Term Investments	+ 0.98	Cash And Short Term Investments

Retained Earnings	- 0.97	Short Long Term Debt Total
Other Stockholder Equity	- 0.96	Retained Earnings
Property Plant And Equipment Gross	- 0.95	Retained Earnings
Total Liab	- 0.94	Retained Earnings
Retained Earnings	- 0.94	Net Debt
Non Current Liabilities Total	- 0.93	Retained Earnings